1-3 of 3
Gregory D. Plowman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity

Available to Purchase
Helen Kotanides, Rose Marie Sattler, Maria B. Lebron, Carmine Carpenito, Juqun Shen, Jingxing Li, David Surguladze, Jaafar N. Haidar, Colleen Burns, Leyi Shen, Ivan Inigo, Anthony L. Pennello, Amelie Forest, Xinlei Chen, Darin Chin, Andreas Sonyi, Michael Topper, Lauren Boucher, Prachi Sharma, Yiwei Zhang, Douglas Burtrum, Ruslan D. Novosiadly, Dale L. Ludwig, Gregory D. Plowman, Michael Kalos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (4): 988–998.
https://doi.org/10.1158/1535-7163.MCT-19-0893
Published: 02 April 2020
View article titled, Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
Open the PDF for Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity in another window
Includes: Supplementary data
Journal Articles

ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

Free
Shripad V. Bhagwat, William T. McMillen, Shufen Cai, Baohui Zhao, Matthew Whitesell, Weihua Shen, Lisa Kindler, Robert S. Flack, Wenjuan Wu, Bryan Anderson, Yan Zhai, Xiu-Juan Yuan, Meghann Pogue, Robert D. Van Horn, Xi Rao, Denis McCann, Andrew J. Dropsey, Jason Manro, Jennie Walgren, Eunice Yuen, Michael J. Rodriguez, Gregory D. Plowman, Ramon V. Tiu, Sajan Joseph, Sheng-Bin Peng
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (2): 325–336.
https://doi.org/10.1158/1535-7163.MCT-19-0183
Published: 06 February 2020
View article titled, ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Open the PDF for ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine in another window
Includes: Supplementary data
Journal Articles

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Free
Jian Du, Lei Yan, Raquel Torres, Xueqian Gong, Huimin Bian, Carlos Marugán, Karsten Boehnke, Carmen Baquero, Yu-Hua Hui, Sonya C. Chapman, Yanzhu Yang, Yi Zeng, Sarah M. Bogner, Robert T. Foreman, Andrew Capen, Gregory P. Donoho, Robert D. Van Horn, Darlene S. Barnard, Jack A. Dempsey, Richard P. Beckmann, Mark S. Marshall, Li-Chun Chio, Yuewei Qian, Yue W. Webster, Amit Aggarwal, Shaoyou Chu, Shobha Bhattachar, Louis F. Stancato, Michele S. Dowless, Phillip W. Iversen, Jason R. Manro, Jennie L. Walgren, Bartley W. Halstead, Matthew Z. Dieter, Ricardo Martinez, Shripad V. Bhagwat, Emiko L. Kreklau, Maria Jose Lallena, Xiang S. Ye, Bharvin K.R. Patel, Christoph Reinhard, Gregory D. Plowman, David A. Barda, James R. Henry, Sean G. Buchanan, Robert M. Campbell
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2207–2219.
https://doi.org/10.1158/1535-7163.MCT-18-0529
Published: 02 December 2019
View article titled, Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy
Open the PDF for Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy in another window
Includes: Supplementary data